{
    "clinical_study": {
        "@rank": "141138", 
        "acronym": "HEP-C-FM", 
        "arm_group": [
            {
                "arm_group_label": "study group", 
                "arm_group_type": "Experimental", 
                "description": "Tablet Nitazoxanide 500mg twice daily will be added to the injection conventional interferon alfa 3 Million International Units alternate days and capsule Ribavirin 400mg-1200mg weekly for six months"
            }, 
            {
                "arm_group_label": "control group", 
                "arm_group_type": "Active Comparator", 
                "description": "Injection conventional interferon alfa 3 Million International Units alternate days and capsule ribavirin 400mg-1200mg weekly for six months"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to investigate if  nitazoxanide used in combination with\n      interferon alfa and ribavirin is effective in treating Hepatitis c infected type 2 Diabetic\n      patients by improving their sustained viral response by more than 80%.Considering that the\n      study is being conducted in a third world country like Pakistan, the standard treatment of\n      hepatitis C is not cost effective. The aim is to introduce a new treatment comparable in\n      efficacy to peginterferon and also cost effective."
        }, 
        "brief_title": "The Role Of Nitazoxanide, Interferon Alfa And Ribavirin In Treatment Of Hepatitis C Infected Type 2 Diabetic Patients", 
        "clinical_results": {
            "baseline": {
                "group_list": {
                    "group": [
                        {
                            "@group_id": "B1", 
                            "description": "Injection conventional interferon alfa 3 Million International Units alternate days and capsule ribavirin 400mg-1200mg weekly for six months\nRibavirin : ribazole\nconventional interferon alfa : Inj interferon 3 Million International Units thrice weekly", 
                            "title": "Control Group"
                        }, 
                        {
                            "@group_id": "B2", 
                            "description": "Tablet Nitazoxanide 500mg twice daily will be added to the injection conventional interferon alfa 3 Million International Units alternate days and capsule Ribavirin 400mg-1200mg weekly for six months\nRibavirin : ribazole\nnitazoxanide : nitazoxanide 500mg twice daily\nconventional interferon alfa : Inj interferon 3 Million International Units thrice weekly", 
                            "title": "Study Group"
                        }, 
                        {
                            "@group_id": "B3", 
                            "description": "Total of all reporting groups", 
                            "title": "Total"
                        }
                    ]
                }, 
                "measure_list": {
                    "measure": [
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": [
                                            {
                                                "@group_id": "B1", 
                                                "@value": "33"
                                            }, 
                                            {
                                                "@group_id": "B2", 
                                                "@value": "33"
                                            }, 
                                            {
                                                "@group_id": "B3", 
                                                "@value": "66"
                                            }
                                        ]
                                    }
                                }
                            }, 
                            "param": "Number", 
                            "title": "Number of Participants", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": [
                                                {
                                                    "@group_id": "B1", 
                                                    "@value": "0"
                                                }, 
                                                {
                                                    "@group_id": "B2", 
                                                    "@value": "0"
                                                }, 
                                                {
                                                    "@group_id": "B3", 
                                                    "@value": "0"
                                                }
                                            ]
                                        }, 
                                        "sub_title": "<=18 years"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": [
                                                {
                                                    "@group_id": "B1", 
                                                    "@value": "33"
                                                }, 
                                                {
                                                    "@group_id": "B2", 
                                                    "@value": "33"
                                                }, 
                                                {
                                                    "@group_id": "B3", 
                                                    "@value": "66"
                                                }
                                            ]
                                        }, 
                                        "sub_title": "Between 18 and 65 years"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": [
                                                {
                                                    "@group_id": "B1", 
                                                    "@value": "0"
                                                }, 
                                                {
                                                    "@group_id": "B2", 
                                                    "@value": "0"
                                                }, 
                                                {
                                                    "@group_id": "B3", 
                                                    "@value": "0"
                                                }
                                            ]
                                        }, 
                                        "sub_title": ">=65 years"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Age", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": [
                                            {
                                                "@group_id": "B1", 
                                                "@spread": "6.07", 
                                                "@value": "47.30"
                                            }, 
                                            {
                                                "@group_id": "B2", 
                                                "@spread": "5.464", 
                                                "@value": "47.21"
                                            }, 
                                            {
                                                "@group_id": "B3", 
                                                "@spread": "5.73", 
                                                "@value": "47.26"
                                            }
                                        ]
                                    }
                                }
                            }, 
                            "dispersion": "Standard Deviation", 
                            "param": "Mean", 
                            "title": "Age", 
                            "units": "years"
                        }, 
                        {
                            "category_list": {
                                "category": [
                                    {
                                        "measurement_list": {
                                            "measurement": [
                                                {
                                                    "@group_id": "B1", 
                                                    "@value": "15"
                                                }, 
                                                {
                                                    "@group_id": "B2", 
                                                    "@value": "14"
                                                }, 
                                                {
                                                    "@group_id": "B3", 
                                                    "@value": "29"
                                                }
                                            ]
                                        }, 
                                        "sub_title": "Female"
                                    }, 
                                    {
                                        "measurement_list": {
                                            "measurement": [
                                                {
                                                    "@group_id": "B1", 
                                                    "@value": "18"
                                                }, 
                                                {
                                                    "@group_id": "B2", 
                                                    "@value": "19"
                                                }, 
                                                {
                                                    "@group_id": "B3", 
                                                    "@value": "37"
                                                }
                                            ]
                                        }, 
                                        "sub_title": "Male"
                                    }
                                ]
                            }, 
                            "param": "Number", 
                            "title": "Gender", 
                            "units": "participants"
                        }, 
                        {
                            "category_list": {
                                "category": {
                                    "measurement_list": {
                                        "measurement": [
                                            {
                                                "@group_id": "B1", 
                                                "@value": "33"
                                            }, 
                                            {
                                                "@group_id": "B2", 
                                                "@value": "33"
                                            }, 
                                            {
                                                "@group_id": "B3", 
                                                "@value": "66"
                                            }
                                        ]
                                    }, 
                                    "sub_title": "Pakistan"
                                }
                            }, 
                            "param": "Number", 
                            "title": "Region of Enrollment", 
                            "units": "participants"
                        }
                    ]
                }
            }, 
            "certain_agreements": {
                "pi_employee": "Principal Investigators are NOT employed by the organization sponsoring the study.", 
                "restrictive_agreement": "There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed."
            }, 
            "outcome_list": {
                "outcome": [
                    {
                        "description": "Sustained viral response ,is negative Hepatitis C Virus(PCR)RNA test six months after end of treatment.", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Injection conventional interferon alfa 3 Million International Units alternate days and capsule ribavirin 400mg-1200mg weekly for six months\nRibavirin : ribazole\nconventional interferon alfa : Inj interferon 3 Million International Units thrice weekly", 
                                    "title": "Control Group"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Tablet Nitazoxanide 500mg twice daily will be added to the injection conventional interferon alfa 3 Million International Units alternate days and capsule Ribavirin 400mg-1200mg weekly for six months\nRibavirin : ribazole\nnitazoxanide : nitazoxanide 500mg twice daily\nconventional interferon alfa : Inj interferon 3 Million International Units thrice weekly", 
                                    "title": "Study Group"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "33"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "33"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "13"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "11"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "Sustained viral response ,is negative Hepatitis C Virus(PCR)RNA test six months after end of treatment.", 
                                    "param": "Number", 
                                    "title": "Sustained Viral Response,", 
                                    "units": "participants"
                                }
                            ]
                        }, 
                        "population": "Sample size has been calculated using Epi-Info 3.5.1 with the following assumptions.\nReported ETR with Interferon + Ribavarin  =  44 % Expected ETR with Interferon + Ribavarin + Nitazoxanide  =  80 % Confidence Level = 95 % Power of Study   = 80% Calculated Sample Size = 66 i.e. 33 in each group.", 
                        "safety_issue": "No", 
                        "time_frame": "48 WEEK", 
                        "title": "Sustained Viral Response,", 
                        "type": "Primary"
                    }, 
                    {
                        "description": "Liver function test,showing resolution of the inflammation of liver parenchyma", 
                        "group_list": {
                            "group": [
                                {
                                    "@group_id": "O1", 
                                    "description": "Injection conventional interferon alfa 3 Million International Units alternate days and capsule ribavirin 400mg-1200mg weekly for six months\nRibavirin : ribazole\nconventional interferon alfa : Inj interferon 3 Million International Units thrice weekly", 
                                    "title": "Control Group"
                                }, 
                                {
                                    "@group_id": "O2", 
                                    "description": "Tablet Nitazoxanide 500mg twice daily will be added to the injection conventional interferon alfa 3 Million International Units alternate days and capsule Ribavirin 400mg-1200mg weekly for six months\nRibavirin : ribazole\nnitazoxanide : nitazoxanide 500mg twice daily\nconventional interferon alfa : Inj interferon 3 Million International Units thrice weekly", 
                                    "title": "Study Group"
                                }
                            ]
                        }, 
                        "measure_list": {
                            "measure": [
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "33"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "33"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "param": "Number", 
                                    "title": "Number of Participants", 
                                    "units": "participants"
                                }, 
                                {
                                    "category_list": {
                                        "category": {
                                            "measurement_list": {
                                                "measurement": [
                                                    {
                                                        "@group_id": "O1", 
                                                        "@value": "11"
                                                    }, 
                                                    {
                                                        "@group_id": "O2", 
                                                        "@value": "11"
                                                    }
                                                ]
                                            }
                                        }
                                    }, 
                                    "description": "Liver function test,showing resolution of the inflammation of liver parenchyma", 
                                    "param": "Number", 
                                    "title": "Normalization of Alanine Transferase Test", 
                                    "units": "participants"
                                }
                            ]
                        }, 
                        "population": "Sample size has been calculated using Epi-Info 3.5.1 with the following assumptions.\nReported ETR with Interferon + Ribavarin  =  44 % Expected ETR with Interferon + Ribavarin + Nitazoxanide  =  80 % Confidence Level = 95 % Power of Study   = 80% Calculated Sample Size = 66 i.e. 33 in each group.", 
                        "safety_issue": "No", 
                        "time_frame": "48week", 
                        "title": "Normalization of Alanine Transferase Test", 
                        "type": "Secondary"
                    }
                ]
            }, 
            "participant_flow": {
                "group_list": {
                    "group": [
                        {
                            "@group_id": "P1", 
                            "description": "Injection conventional interferon alfa 3 Million International Units alternate days and capsule ribavirin 400mg-1200mg weekly for six months\nRibavirin : ribazole\nconventional interferon alfa : Inj interferon 3 Million International Units thrice weekly", 
                            "title": "Control Group"
                        }, 
                        {
                            "@group_id": "P2", 
                            "description": "Tablet Nitazoxanide 500mg twice daily will be added to the injection conventional interferon alfa 3 Million International Units alternate days and capsule Ribavirin 400mg-1200mg weekly for six months\nRibavirin : ribazole\nnitazoxanide : nitazoxanide 500mg twice daily\nconventional interferon alfa : Inj interferon 3 Million International Units thrice weekly", 
                            "title": "Study Group"
                        }
                    ]
                }, 
                "period_list": {
                    "period": {
                        "milestone_list": {
                            "milestone": [
                                {
                                    "participants_list": {
                                        "participants": [
                                            {
                                                "@count": "33", 
                                                "@group_id": "P1"
                                            }, 
                                            {
                                                "@count": "33", 
                                                "@group_id": "P2"
                                            }
                                        ]
                                    }, 
                                    "title": "STARTED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": [
                                            {
                                                "@count": "33", 
                                                "@group_id": "P1"
                                            }, 
                                            {
                                                "@count": "33", 
                                                "@group_id": "P2"
                                            }
                                        ]
                                    }, 
                                    "title": "COMPLETED"
                                }, 
                                {
                                    "participants_list": {
                                        "participants": [
                                            {
                                                "@count": "0", 
                                                "@group_id": "P1"
                                            }, 
                                            {
                                                "@count": "0", 
                                                "@group_id": "P2"
                                            }
                                        ]
                                    }, 
                                    "title": "NOT COMPLETED"
                                }
                            ]
                        }, 
                        "title": "Overall Study"
                    }
                }, 
                "pre_assignment_details": "Initially 153 patients were recruited but only 66 patients were enrolled in the trial based on our inclusion criteria. Following patients were excluded:\n33 because of HCV genotype other than 3\n18 because of normal ALT\n9 with undetectable HCV PCR\n2 because of thyroid dysfunction\n25 were lost to follow up", 
                "recruitment_details": "Data was collected from diabetic patients coming to diabetes management center Services Hospital Lahore. Recruitment started on july 2011 and last patient was recruited in March 2012."
            }, 
            "point_of_contact": {
                "email": "faisalmasud@hotmail.com", 
                "name_or_title": "Prof. Faisal Masud", 
                "organization": "SIMS", 
                "phone": "00923004260213"
            }, 
            "reported_events": {
                "group_list": {
                    "group": [
                        {
                            "@group_id": "E1", 
                            "description": "Injection conventional interferon alfa 3 Million International Units alternate days and capsule ribavirin 400mg-1200mg weekly for six months\nRibavirin : ribazole\nconventional interferon alfa : Inj interferon 3 Million International Units thrice weekly", 
                            "title": "Control Group"
                        }, 
                        {
                            "@group_id": "E2", 
                            "description": "Tablet Nitazoxanide 500mg twice daily will be added to the injection conventional interferon alfa 3 Million International Units alternate days and capsule Ribavirin 400mg-1200mg weekly for six months\nRibavirin : ribazole\nnitazoxanide : nitazoxanide 500mg twice daily\nconventional interferon alfa : Inj interferon 3 Million International Units thrice weekly", 
                            "title": "Study Group"
                        }
                    ]
                }, 
                "other_events": {
                    "category_list": {
                        "category": [
                            {
                                "event_list": {
                                    "event": {
                                        "counts": [
                                            {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "33", 
                                                "@subjects_at_risk": "33"
                                            }, 
                                            {
                                                "@group_id": "E2", 
                                                "@subjects_affected": "33", 
                                                "@subjects_at_risk": "33"
                                            }
                                        ], 
                                        "sub_title": "Total, other adverse events"
                                    }
                                }, 
                                "title": "Total"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": [
                                                {
                                                    "@events": "0", 
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "33"
                                                }, 
                                                {
                                                    "@events": "6", 
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "6", 
                                                    "@subjects_at_risk": "33"
                                                }
                                            ], 
                                            "sub_title": "Diarrhea"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@events": "16", 
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "16", 
                                                    "@subjects_at_risk": "33"
                                                }, 
                                                {
                                                    "@events": "23", 
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "23", 
                                                    "@subjects_at_risk": "33"
                                                }
                                            ], 
                                            "sub_title": "Nausea"
                                        }
                                    ]
                                }, 
                                "title": "Gastrointestinal disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "counts": [
                                                {
                                                    "@events": "29", 
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "29", 
                                                    "@subjects_at_risk": "33"
                                                }, 
                                                {
                                                    "@events": "29", 
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "29", 
                                                    "@subjects_at_risk": "33"
                                                }
                                            ], 
                                            "sub_title": "Flu"
                                        }, 
                                        {
                                            "counts": [
                                                {
                                                    "@events": "1", 
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "1", 
                                                    "@subjects_at_risk": "33"
                                                }, 
                                                {
                                                    "@events": "2", 
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "2", 
                                                    "@subjects_at_risk": "33"
                                                }
                                            ], 
                                            "sub_title": "Dry Cough"
                                        }
                                    ]
                                }, 
                                "title": "Respiratory, thoracic and mediastinal disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": [
                                        {
                                            "assessment": "Non-systematic Assessment", 
                                            "counts": [
                                                {
                                                    "@events": "0", 
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "33"
                                                }, 
                                                {
                                                    "@events": "2", 
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "2", 
                                                    "@subjects_at_risk": "33"
                                                }
                                            ], 
                                            "sub_title": "Alopecia"
                                        }, 
                                        {
                                            "assessment": "Non-systematic Assessment", 
                                            "counts": [
                                                {
                                                    "@events": "0", 
                                                    "@group_id": "E1", 
                                                    "@subjects_affected": "0", 
                                                    "@subjects_at_risk": "33"
                                                }, 
                                                {
                                                    "@events": "2", 
                                                    "@group_id": "E2", 
                                                    "@subjects_affected": "2", 
                                                    "@subjects_at_risk": "33"
                                                }
                                            ], 
                                            "sub_title": "Rash"
                                        }
                                    ]
                                }, 
                                "title": "Skin and subcutaneous tissue disorders"
                            }
                        ]
                    }, 
                    "default_assessment": "Systematic Assessment", 
                    "frequency_threshold": "3"
                }, 
                "serious_events": {
                    "category_list": {
                        "category": [
                            {
                                "event_list": {
                                    "event": {
                                        "counts": [
                                            {
                                                "@group_id": "E1", 
                                                "@subjects_affected": "2", 
                                                "@subjects_at_risk": "33"
                                            }, 
                                            {
                                                "@group_id": "E2", 
                                                "@subjects_affected": "3", 
                                                "@subjects_at_risk": "33"
                                            }
                                        ], 
                                        "sub_title": "Total, serious adverse events"
                                    }
                                }, 
                                "title": "Total"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": [
                                            {
                                                "@events": "1", 
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "33"
                                            }, 
                                            {
                                                "@events": "0", 
                                                "@group_id": "E2", 
                                                "@subjects_affected": "0", 
                                                "@subjects_at_risk": "33"
                                            }
                                        ], 
                                        "sub_title": "hemolysis"
                                    }
                                }, 
                                "title": "Blood and lymphatic system disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": [
                                            {
                                                "@events": "0", 
                                                "@group_id": "E1", 
                                                "@subjects_affected": "0", 
                                                "@subjects_at_risk": "33"
                                            }, 
                                            {
                                                "@events": "2", 
                                                "@group_id": "E2", 
                                                "@subjects_affected": "2", 
                                                "@subjects_at_risk": "33"
                                            }
                                        ], 
                                        "sub_title": "Acute hepatitis"
                                    }
                                }, 
                                "title": "Hepatobiliary disorders"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": [
                                            {
                                                "@events": "1", 
                                                "@group_id": "E1", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "33"
                                            }, 
                                            {
                                                "@events": "0", 
                                                "@group_id": "E2", 
                                                "@subjects_affected": "0", 
                                                "@subjects_at_risk": "33"
                                            }
                                        ], 
                                        "sub_title": "diabetic foot"
                                    }
                                }, 
                                "title": "Infections and infestations"
                            }, 
                            {
                                "event_list": {
                                    "event": {
                                        "counts": [
                                            {
                                                "@events": "0", 
                                                "@group_id": "E1", 
                                                "@subjects_affected": "0", 
                                                "@subjects_at_risk": "33"
                                            }, 
                                            {
                                                "@events": "1", 
                                                "@group_id": "E2", 
                                                "@subjects_affected": "1", 
                                                "@subjects_at_risk": "33"
                                            }
                                        ], 
                                        "sub_title": "Depression"
                                    }
                                }, 
                                "title": "Psychiatric disorders"
                            }
                        ]
                    }, 
                    "default_assessment": "Systematic Assessment"
                }, 
                "time_frame": "1 year and 8 months"
            }
        }, 
        "completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Hepatitis C, Chronic", 
            "DIABETES MELLITUS Type 2"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2", 
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "detailed_description": {
            "textblock": "After taking proper informed consent from patients, patients who fulfill the research\n      criteria are randomized into 2 groups (control/study). Patients in both groups will be\n      treated with conventional interferon alfa and Ribavirin.Those in study group will be given\n      tab nitazoxanide 500mg twice daily in addition to conventional treatment. The patients will\n      be followed up at regular intervals: 0,4,12,24,48 week.At each visit Hepatitis C\n      Virus(PCR)RNA, Liver function tests, complete blood count will be done."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Hepatitis C genotype 3a\n\n          -  Hepatitis C Virus(PCR)RNA Detected\n\n          -  Alanine transaminase >60\n\n          -  Diabetic HbA1c<8\n\n          -  BMI>23\n\n        Exclusion Criteria:\n\n          -  Previously treated Hepatitis C patients\n\n          -  Pregnant females\n\n          -  Decompensated liver disease,Child class B OR above\n\n          -  Thyroid disease,Thyroid stimulating hormone>10,0.05\n\n          -  Absolute neutrophil count<1500,Platelets<80,000,Hb<10g Female,<11g Male\n\n          -  Severe cardiac disease,New York Heart Association2\n\n          -  Moderate to severe depression assessed by Beck Depression Inventory scale"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "35 Years"
        }, 
        "enrollment": {
            "#text": "66", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "January 8, 2013", 
        "firstreceived_results_date": "March 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01770483", 
            "org_study_id": "SIMS"
        }, 
        "intervention": [
            {
                "arm_group_label": "study group", 
                "description": "nitazoxanide 500mg twice daily", 
                "intervention_name": "nitazoxanide", 
                "intervention_type": "Drug", 
                "other_name": [
                    "tablet nizonide500mg", 
                    "tablet atizox500mg"
                ]
            }, 
            {
                "arm_group_label": [
                    "study group", 
                    "control group"
                ], 
                "description": "Inj interferon 3 Million International Units thrice weekly", 
                "intervention_name": "conventional interferon alfa", 
                "intervention_type": "Drug", 
                "other_name": "Inj uniferon 3 Million International Units"
            }, 
            {
                "arm_group_label": [
                    "study group", 
                    "control group"
                ], 
                "description": "ribazole", 
                "intervention_name": "Ribavirin", 
                "intervention_type": "Drug", 
                "other_name": "Ribavirin 400mg-1200mg"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Interferon-alpha", 
                "Interferon Alfa-2a", 
                "Interferons", 
                "Ribavirin", 
                "Nitazoxanide"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Nitazoxanide,", 
            "Sustained viral response", 
            "Type 2 DIABETICS"
        ], 
        "lastchanged_date": "September 15, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Lahore", 
                    "country": "Pakistan", 
                    "state": "Punjab"
                }, 
                "name": "Endocrinology and Diabetes management centre"
            }
        }, 
        "location_countries": {
            "country": "Pakistan"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Role Of Nitazoxanide, Interferon Alfa And Ribavirin In Treatment Of Hepatitis C Infected Type 2 Diabetic Patients", 
        "overall_official": [
            {
                "affiliation": "Principal SIMS/Services hospital lahore", 
                "last_name": "FAISAL MASUD, FRCP", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "Senior registrar ,Services hospital lahore/SIMS", 
                "last_name": "AMENA MIRZA, MRCP,FCPS", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "House Officer Services Hospital Lahore", 
                "last_name": "Madiha Fida, MBBS", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Pakistan: Research Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "March 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Sustained viral response ,is negative Hepatitis C Virus(PCR)RNA test six months after end of treatment.", 
            "measure": "Sustained Viral Response,", 
            "safety_issue": "No", 
            "time_frame": "48 WEEK"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01770483"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Services Institute of Medical Sciences, Pakistan", 
            "investigator_full_name": "Prof. Faisal Masud", 
            "investigator_title": "Principal SIMS", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Liver function test,showing resolution of the inflammation of liver parenchyma", 
            "measure": "Normalization of Alanine Transferase Test", 
            "safety_issue": "No", 
            "time_frame": "48week"
        }, 
        "source": "Services Institute of Medical Sciences, Pakistan", 
        "sponsors": {
            "collaborator": {
                "agency": "Getz Pharma", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Services Institute of Medical Sciences, Pakistan", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "July 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "September 2013"
    }
}